Therese Rubio, GBDS, VBS - Partner - Nava Benefits | LinkedIn
WEBGreater San Diego Area. As a Client Executive at Marsh & McLennan Agency, I am dedicated to building lasting relationships with my customers. As such, I strive to listen to my clients and...
- Title: On a mission to #fixhealthcare
- Location: Nava Benefits
- 500+ connections
“I Want to Be a Changemaker”: Meet Therese Rubio, Nava Partner
WEBJun 9, 2022 · As a self-described data nerd, Therese Rubio brings a strategic approach to supporting clients throughout the benefits lifecycle. Learn more about Therese’s commitment to helping employees understand their healthcare, how she thinks brokers can take action to better support HR leaders, and her vision for the future of benefits.
Therese Rubio Profiles - Facebook
WEBView the profiles of people named Therese Rubio. Join Facebook to connect with Therese Rubio and others you may know. Facebook gives people the power to...
Therese Rubio, GBDS, VBS - Nava Benefits | LinkedIn
WEBView Therese Rubio, GBDS, VBS’ profile on LinkedIn, a professional community of 1 billion members. Experience: Nava Benefits · Education: University of San Diego · Location: San Diego · 500 ...
- 500+ connections
- Location: Nava Benefits
Therese Rubio, GBDS, VBS’ Post - LinkedIn
WEBSharing our story in working with the amazing Therese Rubio, GBDS, VBS at Nava Benefits.
WEBSep 14, 2022 · IMMUNOMONITORING in patients receiving CAR-T cells. Marie Thérèse Rubio, MD, PhD. Service d’Hématologie, CHRU Nancy, France. CNRS UMR 7365 IMoPa, Team 6, Université de Lorraine, Nancy, France. LTR LTR.
Biologie, concepts et principes des CAR-T cells - PubMed
WEBGenetically modified T-cells, called "CAR (chimeric antigen receptors) -T cells", have yielded impressive clinical results in the treatment of relapsed or refractory lymphoid hematological malignancies after conventional treatments …
Author notes - American Society of Hematology
WEBNov 13, 2019 · However, inconsistent results of the influence of CD34+ cells dose on the incidence of graft-versus-host disease (GVHD), disease control and survival have been reported in studies published thus far. Allo-HCT remains the only potentially curative treatment modality for eligible patients with myelofibrosis (MF).
Therese Rubio - Facebook
WEBTherese Rubio is on Facebook. Join Facebook to connect with Therese Rubio and others you may know. Facebook gives people the power to share and makes the world more open and connected.
Impact of donor-derived CD34 + infused cell dose on outcomes of ...
WEBDec 1, 2021 · In a model with interaction, for patients transplanted from a MSD, higher CD34 + dose was associated with improved overall survival (HR, 0.63; P = 0.04) and relapse-free survival (HR, 0.61; P =...
Skip to content